Taysha (TSHA) Q4 2025 Earnings Call Transcript

Key event: REVEAL Phase 1/2 Part A showed a 100% response rate in 10 patients and an 83% response rate at six months (5/6 high‑dose patients), and TSHA‑102 received FDA Breakthrough Therapy designation with written FDA alignment on pivotal and ASPIRE trial designs enabling pooling of datasets for a potential streamlined BLA. Operational/CMC update: BLA‑enabling PPQ lots will be initiated in 2026 and completed by year‑end, and FDA agreed comparability allowing pooling of REVEAL Phase 1/2, pivotal, and ASPIRE data. Financials: FY2025 R&D was $86.4M (vs $66.0M in 2024), G&A $33.9M (vs $29.0M), net loss $109.0M, cash $319.8M as of 12/31/2025 with $50M ATM raised in Q4 2025; management expects runway into 2028.

Analysis

The program’s regulatory choreography (pooling datasets + early CMC alignment) materially raises the value of early positive signals because it makes those signals actionable — not just directional. That magnifies the impact of an interim readout relative to a typical program: a clean interim can shorten time-to-revenue optionality, while a regulatory ask for longer follow-up converts upside into execution risk rather than scientific risk.

Manufacturing and commercial footprint are the likely non-clinical chokepoints. Intrathecal delivery lowers the bar for site adoption, but scaling AAV supply, PPQ execution and a commercial inventory build are multi-quarter, capital- and capacity-intensive activities; delays or CDMO hiccups will compress realized value even if clinical data are strong. Parallelly, payer negotiations will hinge on demonstrable functional gains (not biomarker changes), so the translation of milestone metrics into durable real-world benefits is the key commercial gating item.

Consensus appears to price a smooth operational path post-readout; that’s the contrarian entry. The single largest downside that investors often underweight is non-clinical: a regulatory insistence on longer durability or a manufacturing shortfall will force either dilution or a staggered launch. Hedge the binary clinical exposure and size positions so that execution/dilution scenarios (not just efficacy) drive your stop-loss and upside targets.

Key Decisions for Investors

• Buy TSHA 9–12 month call spread (long calls / short higher-strike calls) sized at 1–2% of portfolio — asymmetric way to capture upside from an upcoming pivotal readout while capping premium risk; if regulatory feedback asks for longer follow-up, take profits or roll down into longer-dated calls to preserve optionality.
• Pair trade: Long TSHA equity (small size) / Short NGNE equity (equal notional) over 6–12 months — expresses view that a faster-onset construct + regulatory alignment will re-rate TSHA versus single-stranded competitors; cap position size and buy protective puts on the short leg if NGNE announces positive unexpected durability data.
• Long SRPT (stock or 12–24 month call) as a tactical infrastructure play — benefits from any broader gene-therapy market re-pricing and payer acceptance precedent; downside is program-specific safety/regulatory headlines, so keep position moderate and use delta-hedged calls if available.
• Establish a biotech downside hedge (XLV/IBB put spread or long VIXE/short calls) for 3–9 months sized to offset ~30–50% of TSHA exposure — protects against binary negative regulatory outcomes or headline-led sector derating that would disproportionally hit small-cap gene-therapy names.